Symbiotec Pharmalab came to market through an IPO that opened on 24 August 2026 and closed on 27 August 2026, and the shares listed on 1 September 2026 on BSE, NSE. The price band was ₹938 to ₹988 per share and one lot was 15 shares, so the minimum application was ₹14,820. The issue size was ₹1757 crore. It combined a fresh issue of new shares with an offer for sale by existing shareholders.
It listed at ₹988, flat against the issue price of ₹988. MUFG Intime India Pvt.Ltd was the registrar to the issue, and JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt.Ltd were the lead managers.
As of 27 August 2026.
| Day |
|---|
| 1 |
| 2 |
| 3 |
| 4 |
| 5 |
Overall the issue was subscribed 75.06 times.
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a biopharmaceutical and bio technological company whose operations include development and manufacture of active pharmaceutical ingredients, nutritional ingredients and specialized products for domestic and international markets. The firm focuses on research-based manufacturing, quality and sustainability. It provides ingredients that contribute towards growth in pharmaceutical, nutraceutical and wellness industries.
Having over three decades of industry experience, the firm has grown from a laboratory-scale manufacturer of steroidal-hormone APIs in 1995 to an industrial scale backward-integration platform having approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea among others.
By June 30, 2025, the firm had two industrial-scale API manufacturing plants with a maximum capacity of 584.67 metric tonnes (MT) of chemical synthesis and 300 kilolitres of fermentation capacity.
As described in the offer document.
| Metric | 31-Mar-26 | 31-Mar-25 | 31-Mar-24 |
|---|
Symbiotec Pharmalab Limited finalised its anchor investor allocation on August 21, 2026, raising ₹526.20 crore from 34 anchor investors at an anchor price of ₹988 per share. The anchor book comprises 53,25,909 equity shares, with domestic mutual funds receiving 60.06% of the allocation through 11 fund houses across 19 schemes, including ICICI Prudential, HDFC, Motilal Oswal, Mirae Asset, and Edelweiss Mutual Fund, among others.
Life insurance companies received 7.98% through 3 participants — Tata AIA Life Insurance, Bajaj Life Insurance, and Bharti AXA Life Insurance. The remaining allocation went to a mix of foreign and domestic institutional investors, led by Ashoka Whiteoak ICAV – Ashoka Whiteoak Emerging Markets Equity Fund at 8.55%, followed by Prazim Trading and Investment Company Private Limited and Manulife Global Fund – India Equity Fund at 4.75% each, and ValueQuest Founders Conviction LVF at 1.90%
Anil Satwani, Kashish Satwani, Sushil Satwani, Satwani Holdings LLP.
Work out the listing gain for this IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Symbiotec Pharmalab IPO was a ₹1,757 crore book-built issue, comprising a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore. It was priced at ₹938–₹988 per share with a lot size of 15 shares (₹14,820). The IPO was open from August 24 to August 27, 2026 and was subscribed 75.06x. Shares listed on BSE and NSE on September 1, 2026 at ₹988, in line with the issue price of ₹988. MUFG Intime India Pvt. Ltd.
is the registrar. JM Financial Ltd. and 3 other book running lead managers manage the issue.
The price band of Symbiotec Pharmalab IPO is ₹938 to ₹988 per share.
The lot size of Symbiotec Pharmalab IPO is 15 shares.
The minimum investment for Symbiotec Pharmalab IPO is approximately ₹14,820 based on the upper price band.
The allotment date of Symbiotec Pharmalab IPO is Aug 28, 2026.
No GMP quote could be verified as recorded before Symbiotec Pharmalab IPO listed. A grey-market observation of ₹185 per share was recorded on 1 Sep 2026, 6:30 AM IST, but without a verified listing timestamp it is not treated as the final pre-listing GMP. The shares listed at ₹988. GMP is unofficial and does not forecast or guarantee the actual listing price.
Symbiotec Pharmalab IPO listed on Sep 1, 2026. It was issued at ₹988.0(NSE) and is currently around ₹1244.00 as on 30-Oct-2026 3:30 PM, which is approximately 25.9% versus issue price. The 52-week high is ₹1,309.90.
You can check Symbiotec Pharmalab IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Symbiotec Pharmalab IPO allotment status on Rupix for quick and easy access.
₹938 to ₹988 per share, against a face value of ₹2. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 15 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹14,820.
₹14,820, for one lot of 15 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 24 August 2026 and closed on 27 August 2026.
The basis of allotment was published on 28 August 2026 by MUFG Intime India Pvt.Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 1 September 2026 on BSE, NSE, opening at ₹988.
The issue size was ₹1757 crore. The fresh issue was 15,21,261 shares (aggregating up to ₹150 crore). The offer for sale was 1,62,65,181 shares (aggregating up to ₹1607 crore).
It listed at ₹988 against an issue price of ₹988, a gain of 0 percent on listing day.